☆ 4.6 Article

[I-125]INFT: Synthesis and Evaluation of a New Imaging Agent for Tau Protein in Post-Mortem Human Alzheimer's Disease Brain

MOLECULES (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Development of [124/125I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer's Disease

Thrisha T. T. Reddy et al.

Summary: The study introduces a radioiodinated imaging agent called IAZA, which can image A beta plaques in the brains of Alzheimer's disease patients. IAZA exhibits high binding affinity and can differentiate A beta plaques in gray matter and white matter, making it a potentially valuable tool for PET or SPECT imaging studies.

MOLECULES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Measurement of Aβ Amyloid Plaques and Tau Protein in Postmortem Human Alzheimer's Disease Brain by Autoradiography Using [18F]Flotaza, [125I]IBETA, [124/125I]IPPI and Immunohistochemistry Analysis Using QuPath

Rommani Mondal et al.

Summary: High-resolution scans of immunohistochemical stains and radioligand autoradiography provide valuable information about the distribution of A beta plaques and Tau in Alzheimer's disease brain slices. Accurate assessment of these proteinopathies is crucial for understanding the progression of AD pathology. This study aimed to develop a quantitative method for analyzing IHC-autoradiography images.

BIOMEDICINES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Comparison of Monoamine Oxidase-A, A beta Plaques, Tau, and Translocator Protein Levels in Postmortem Human Alzheimer's Disease Brain

Amina U. Syed et al.

Summary: Increased MAO-A activity is detrimental to neurodegeneration in AD. We compared biomarkers in AD and found increased levels of MAO-A, A beta plaques, tau, and TSPO. The positive correlations between MAO-A activity and A beta plaques and tau support the potential use of MAO-A as a biomarker for AD in the anterior cingulate cortex.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Geriatrics & Gerontology

Positron Emission Tomography in Animal Models of Tauopathies

Lei Cao et al.

Summary: This study discusses the usefulness of PET and recently developed tracers in evaluating the pathophysiology in tauopathy animal models. Outstanding challenges and future prospects are pointed out to visualize tau-related pathophysiological changes in the brain of tauopathy disease animal models.

FRONTIERS IN AGING NEUROSCIENCE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Tau PET Imaging in Neurodegenerative Disorders

Colin Groot et al.

Summary: The introduction of PET ligands that bind tau pathology has allowed for the quantification and visualization of tau pathology in aging and Alzheimer's disease. While these ligands are effective in binding tau aggregates in advanced stages of AD, their binding in non-AD tauopathies is weaker and overlaps with known off-target binding regions. An increased neocortical tau PET signal holds important prognostic information, and tau PET shows great potential as a prognostic marker in symptomatic stages of AD. For differential diagnosis, tau PET is primarily useful in distinguishing AD dementia from other neurodegenerative diseases, but its performance decreases in the mild cognitive impairment stage of AD.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients

Greet Vanderlinden et al.

Summary: This article examines the use of [F-18]MK-6240 in the quantification of neurofibrillary tangles in Alzheimer's disease. The study shows that [F-18]MK-6240 has excellent short-term test-retest reliability, making it suitable for longitudinal studies. Additionally, the study finds that extracerebral uptake of [F-18]MK-6240 varies among individuals, with age and sex being associated factors. However, the extracerebral uptake remains stable within individuals over a 2-year time period.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Cell Biology

Elevated Monoamine Oxidase-A in Anterior Cingulate of Post-Mortem Human Parkinson's Disease: A Potential Surrogate Biomarker for Lewy Bodies?

Jogeshwar Mukherjee et al.

Summary: This study evaluated the use of anti-ubiquitin immunohistochemistry for Lewy bodies and correlated it with monoamine oxidase-A using the imaging agent [F-18]FAZIN3. The findings showed the presence of Lewy bodies in all Parkinson's disease brains and increased binding of [F-18]FAZIN3 to MAO-A in PD. This suggests that [F-18]FAZIN3 could be a potential novel PET imaging approach.

CELLS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

[124I]IBETA: A New Aβ Plaque Positron Emission Tomography Imaging Agent for Alzheimer's Disease

Grace A. H. Nguyen et al.

Summary: This study evaluated the use of iodine-124 radioiodinated pyridyl benzofuran derivative in PET imaging of A13 plaques and reported the results of binding experiments in vitro and in vivo.

MOLECULES (2022)

Add to Collection

Article Clinical Neurology

Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study

Santiago Bullich et al.

Summary: This study aimed to evaluate tau deposition using F-18-PI-2620 PET in beta-amyloid positive subjects with mild cognitive impairment (MCI) or mild AD dementia, and investigate its correlation with amyloid deposition, CSF assessment, hippocampal volume, and cognition. The results showed significant associations between tau deposition and hippocampal volume, CSF biomarkers, and amyloid-beta load. The quantifiable increases in F-18-PI-2620 SUVR in regions with early tau deposition support the hypothesis that cortical tau is associated with cognitive impairment in AD. The study highlights the utility of F-18-PI-2620 PET in assessing tau deposits in early AD cases.

ALZHEIMERS RESEARCH & THERAPY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

[18F]Nifene PET/CT Imaging in Mice: Improved Methods and Preliminary Studies of α4β2*Nicotinic Acetylcholinergic Receptors in Transgenic A53T Mouse Model of α-Synucleinopathy and Post-Mortem Human Parkinson's Disease

Anthony-David T. Campoy et al.

Summary: This study reported the binding of [F-18]nifene to nAChRs in Parkinson's disease using a transgenic mouse model and postmortem human brain sections. Improved radiosynthesis methods and PET/CT procedures in mice were developed to establish optimal imaging time and observe decreases in [F-18]nifene binding both in vivo and in vitro. Confirmation of Lewy bodies and alpha-synuclein aggregates in human PD brain sections further supported the potential of [F-18]nifene as a valuable tool for PET imaging studies of PD.

MOLECULES (2021)

Add to Collection

Article Chemistry, Medicinal

Development and evaluation of [18F]Flotaza for Aβ plaque imaging in postmortem human Alzheimer's disease brain

Harsimran Kaur et al.

Summary: The study developed a new fluorine-18 PET radiotracer [F-18]Flotaza for Aβ plaque imaging, showing high binding affinity in human Aβ plaques. Efficient radiosynthesis of [F-18]Flotaza demonstrated significant imaging capabilities in AD brain tissues.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)

Add to Collection

Article Chemistry, Medicinal

Structure-Activity Relationships of Radioiodinated 6,5,6-Tricyclic Compounds for the Development of Tau Imaging Probes

Hiroyuki Watanabe et al.

ACS MEDICINAL CHEMISTRY LETTERS (2020)

Add to Collection

Article Clinical Neurology

18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases

David N. Soleimani-Meigooni et al.

BRAIN (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand F-18-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls

Tobey J. Betthauser et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase

Lindsey R. Drake et al.

ACS CHEMICAL NEUROSCIENCE (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease

Michael Honer et al.

JOURNAL OF NUCLEAR MEDICINE (2018)

Add to Collection

Article Chemistry, Medicinal

Dual targeting agents for A beta plaque/P-glycoprotein and A beta plaque/nicotinic acetylcholine alpha 4 beta 2*receptors-potential approaches to facilitate A beta plaque removal in Alzheimer's disease brain

Gurleen K. Samra et al.

MEDICINAL CHEMISTRY RESEARCH (2018)

Add to Collection

Review Clinical Neurology

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

Victor L. Villemagne et al.

NATURE REVIEWS NEUROLOGY (2018)

Add to Collection

Article Chemistry, Medicinal

Structure-Activity Relationships of Radioiodinated Benzoimidazopyridine Derivatives for Detection of Tau Pathology

Sho Kaide et al.

ACS MEDICINAL CHEMISTRY LETTERS (2018)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles

Eric D. Hostetler et al.

JOURNAL OF NUCLEAR MEDICINE (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

124I-Epidepride: A PET radiotracer for extended imaging of dopamine D2/D3 receptors

Suresh Pancley et al.

NUCLEAR MEDICINE AND BIOLOGY (2014)

Add to Collection

Article Neurosciences

Striatal and Extrastriatal MicroPET Imaging of D2/D3 Dopamine Receptors in Rat Brain With [18F] Fallypride and [18F] Desmethoxyfallypride

Cristian C. Constantinescu et al.

SYNAPSE (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.